Cells keep their identity through chemical marks on the genome — chiefly DNA methylation at CpG sites — that decide which genes run. With age, the pattern drifts: marks appear where they should not and vanish where they should be. The drift is measurable and is called epigenetic aging.
An algorithm that reads methylation at selected CpG sites and outputs an estimated biological age. Steve Horvath's 2013 multi-tissue clock (353 CpG sites) was the first to work across nearly all human tissues; later clocks track mortality risk and disease. Clocks are the ruler every rejuvenation claim must answer to.
Oct4, Sox2, Klf4 and c-Myc (OSKM) — the four transcription factors Takahashi and Yamanaka used at Kyoto University in 2006 to revert adult cells to pluripotency. Dropping c-Myc gives OSK, the trio the Sinclair lab used for in-vivo rejuvenation. Yamanaka shared the 2012 Nobel Prize with John Gurdon.
Applying Yamanaka factors briefly and in a controlled pulse instead of continuously. Full reprogramming erases cell identity (and risks tumours); a partial pulse resets epigenetic age while the cell keeps its job. Ocampo et al. demonstrated the principle in living mice in 2016.
The research goal of writing the youthful epigenetic pattern back — restoring the methylation landscape a tissue had when it was young — without erasing what the cell is. Partial reprogramming, chemical reprogramming and targeted epigenome editing are the routes being explored. Read the credited timeline on The Story.
In cells and in mice, repeatedly: Ocampo et al. (Cell 2016) ameliorated age-associated hallmarks in mice; Lu et al. (Nature 2020) restored vision in old and glaucomatous mice; Gill et al. (eLife 2022) rewound human fibroblasts by roughly 30 years on methylation clocks. In humans, no therapy has completed clinical proof of epigenetic age reversal — anyone claiming otherwise is selling ahead of the data.
Because the mouse and cell data convinced serious capital that cellular rejuvenation is an engineering problem. Altos Labs launched in 2022 with about $3 billion; Calico has operated under Alphabet since 2013; Retro Biosciences launched in 2022 with $180M from Sam Altman and a stated goal of ten extra healthy years. Investment is not evidence — but it funds the evidence.
Panacea runs a research programme in peptide- and enzyme-mediated epigenetic modulation, led by biochemist and AAC designer Bogdan Dicoias: designer molecules aimed at the epigenome's writers, erasers and readers, where dose and targeting can be engineered. It is a research direction — Panacea claims no rejuvenation results and publishes no data it does not have.
One is registered: NCT07290244, Life Biosciences' ER-100 — a Phase 1, single-dose, open-label tolerability study in which an engineered AAV delivers the OSK trio (OCT4, SOX2, KLF4) into one eye of participants with open-angle glaucoma or NAION, switched on by doxycycline. Recruiting since March 2026, 18 participants estimated. No human reprogramming trial has completed, and none has posted an efficacy or methylation-clock result — so the answer to "has age reversal been demonstrated in humans" remains no. Registry status checked against ClinicalTrials.gov (API v2) on 2026-09-08; other registries, company pipelines and preprints were not searched. Registry record.